Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals

Antivir Ther. 2006;11(8):1097-101.


Background: Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic.

Methods: Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of hepatitis C infection with pegylated interferon (peg-IFN) therapy.

Results: Early treatment resulted in sustained virological response in 61% of patients. Peg-IFN alone showed similar treatment response rates and lower incidence of anaemia compared with peg-IFN+ribavirin combination therapy. Higher treatment response rates were observed in patients treated over 48 weeks compared with 24 weeks.

Conclusions: Treatment of hepatitis C in HIV-positive individuals in the acute phase of infection leads to high rates of sustained virological response. Optimal time and mode of therapy have yet to be defined.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • HIV Infections / complications*
  • Hepatitis C / drug therapy*
  • Hepatitis C / etiology
  • Hepatitis C / transmission
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins
  • Sexually Transmitted Diseases, Viral / drug therapy
  • Sexually Transmitted Diseases, Viral / etiology
  • Sexually Transmitted Diseases, Viral / transmission


  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2b
  • peginterferon alfa-2a